98 related articles for article (PubMed ID: 14748658)
1. Targeted therapies in oncology: in the crosshairs or at the crossroads?
Higa GM
Expert Rev Anticancer Ther; 2004 Feb; 4(1):61-75. PubMed ID: 14748658
[TBL] [Abstract][Full Text] [Related]
2. The role of polypeptide growth factors in human carcinomas: new targets for a novel pharmacological approach.
Favoni RE; de Cupis A
Pharmacol Rev; 2000 Jun; 52(2):179-206. PubMed ID: 10835099
[TBL] [Abstract][Full Text] [Related]
3. Signal transduction pathways as novel therapy targets in lung cancer.
Reinmuth N; Mesters RM; Bieker R; Hoffknecht P; Berdel WE; Thomas M
Lung Cancer; 2004 Aug; 45 Suppl 2():S177-86. PubMed ID: 15552798
[TBL] [Abstract][Full Text] [Related]
4. New paradigms in anticancer therapy: targeting multiple signaling pathways with kinase inhibitors.
Faivre S; Djelloul S; Raymond E
Semin Oncol; 2006 Aug; 33(4):407-20. PubMed ID: 16890796
[TBL] [Abstract][Full Text] [Related]
5. Role of Raf kinase in cancer: therapeutic potential of targeting the Raf/MEK/ERK signal transduction pathway.
Gollob JA; Wilhelm S; Carter C; Kelley SL
Semin Oncol; 2006 Aug; 33(4):392-406. PubMed ID: 16890795
[TBL] [Abstract][Full Text] [Related]
6. Rational targeting of Notch signaling in cancer.
Rizzo P; Osipo C; Foreman K; Golde T; Osborne B; Miele L
Oncogene; 2008 Sep; 27(38):5124-31. PubMed ID: 18758481
[TBL] [Abstract][Full Text] [Related]
7. Molecular signature and therapeutic perspective of the epithelial-to-mesenchymal transitions in epithelial cancers.
Sabbah M; Emami S; Redeuilh G; Julien S; Prévost G; Zimber A; Ouelaa R; Bracke M; De Wever O; Gespach C
Drug Resist Updat; 2008; 11(4-5):123-51. PubMed ID: 18718806
[TBL] [Abstract][Full Text] [Related]
8. Surviving cell death through epidermal growth factor (EGF) signal transduction pathways: implications for cancer therapy.
Henson ES; Gibson SB
Cell Signal; 2006 Dec; 18(12):2089-97. PubMed ID: 16815674
[TBL] [Abstract][Full Text] [Related]
9. Molecular neuro-oncology and the development of targeted therapeutic strategies for brain tumors. Part 4: p53 signaling pathway.
Newton HB
Expert Rev Anticancer Ther; 2005 Feb; 5(1):177-91. PubMed ID: 15757449
[TBL] [Abstract][Full Text] [Related]
10. New approaches in metastatic melanoma: biological and molecular targeted therapies.
Lejeune FJ; Rimoldi D; Speiser D
Expert Rev Anticancer Ther; 2007 May; 7(5):701-13. PubMed ID: 17492933
[TBL] [Abstract][Full Text] [Related]
11. Cellular and molecular signal transduction pathways modulated by rituximab (rituxan, anti-CD20 mAb) in non-Hodgkin's lymphoma: implications in chemosensitization and therapeutic intervention.
Jazirehi AR; Bonavida B
Oncogene; 2005 Mar; 24(13):2121-43. PubMed ID: 15789036
[TBL] [Abstract][Full Text] [Related]
12. Heat shock protein 90: a unique chemotherapeutic target.
Cullinan SB; Whitesell L
Semin Oncol; 2006 Aug; 33(4):457-65. PubMed ID: 16890800
[TBL] [Abstract][Full Text] [Related]
13. [Frontier of mycobacterium research--host vs. mycobacterium].
Okada M; Shirakawa T
Kekkaku; 2005 Sep; 80(9):613-29. PubMed ID: 16245793
[TBL] [Abstract][Full Text] [Related]
14. Signal transduction pathways: the molecular basis for targeted therapies.
Ethier SP
Semin Radiat Oncol; 2002 Jul; 12(3 Suppl 2):3-10. PubMed ID: 12174339
[TBL] [Abstract][Full Text] [Related]
15. Key cancer cell signal transduction pathways as therapeutic targets.
Bianco R; Melisi D; Ciardiello F; Tortora G
Eur J Cancer; 2006 Feb; 42(3):290-4. PubMed ID: 16376541
[TBL] [Abstract][Full Text] [Related]
16. New targets and targeted drugs for the treatment of cancer: an outlook to pediatric oncology.
Rossig C; Juergens H; Berdel WE
Pediatr Hematol Oncol; 2011 Oct; 28(7):539-55. PubMed ID: 21936619
[TBL] [Abstract][Full Text] [Related]
17. Molecular-targeted therapies: lessons from years of clinical development.
Rosa DD; Ismael G; Lago LD; Awada A
Cancer Treat Rev; 2008 Feb; 34(1):61-80. PubMed ID: 17826917
[TBL] [Abstract][Full Text] [Related]
18. Antineoplastic effect of proliferation signal inhibitors: from biology to clinical application.
Bertoni E; Salvadori M
J Nephrol; 2009; 22(4):457-62. PubMed ID: 19662600
[TBL] [Abstract][Full Text] [Related]
19. Autophagy signaling in cancer and its potential as novel target to improve anticancer therapy.
Moretti L; Yang ES; Kim KW; Lu B
Drug Resist Updat; 2007; 10(4-5):135-43. PubMed ID: 17627865
[TBL] [Abstract][Full Text] [Related]
20. Targeted therapy: for kids, too.
Corey SJ
Pediatr Blood Cancer; 2005 Oct; 45(5):623-34. PubMed ID: 15704219
[TBL] [Abstract][Full Text] [Related]
[Next] [New Search]